Bridge City Capital LLC Has $5.40 Million Stock Position in LeMaitre Vascular, Inc. $LMAT

Bridge City Capital LLC decreased its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 9.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 66,623 shares of the medical instruments supplier’s stock after selling 7,235 shares during the period. LeMaitre Vascular accounts for approximately 1.6% of Bridge City Capital LLC’s holdings, making the stock its 23rd biggest holding. Bridge City Capital LLC owned about 0.29% of LeMaitre Vascular worth $5,403,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. MAI Capital Management acquired a new position in LeMaitre Vascular during the 3rd quarter worth about $38,000. Geneos Wealth Management Inc. lifted its position in LeMaitre Vascular by 250.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after buying an additional 398 shares in the last quarter. EverSource Wealth Advisors LLC acquired a new position in LeMaitre Vascular during the 2nd quarter worth about $47,000. GAMMA Investing LLC raised its holdings in LeMaitre Vascular by 32.7% during the 4th quarter. GAMMA Investing LLC now owns 727 shares of the medical instruments supplier’s stock worth $59,000 after purchasing an additional 179 shares during the last quarter. Finally, Quarry LP raised its holdings in LeMaitre Vascular by 267.2% during the 3rd quarter. Quarry LP now owns 727 shares of the medical instruments supplier’s stock worth $64,000 after purchasing an additional 529 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Stock Performance

Shares of NASDAQ:LMAT opened at $91.96 on Friday. The company has a current ratio of 14.32, a quick ratio of 12.20 and a debt-to-equity ratio of 0.42. The stock has a market capitalization of $2.10 billion, a P/E ratio of 33.93, a P/E/G ratio of 2.55 and a beta of 0.54. The business has a 50-day moving average price of $104.09 and a two-hundred day moving average price of $96.01. LeMaitre Vascular, Inc. has a 1-year low of $79.00 and a 1-year high of $118.01.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of $0.66 by $0.02. The company had revenue of $66.55 million during the quarter, compared to analysts’ expectations of $66.67 million. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.LeMaitre Vascular’s revenue was up 11.1% on a year-over-year basis. During the same period in the prior year, the business posted $0.48 EPS. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Equities analysts predict that LeMaitre Vascular, Inc. will post 3 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Thursday, May 21st were paid a $0.25 dividend. The ex-dividend date of this dividend was Thursday, May 21st. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.1%. LeMaitre Vascular’s dividend payout ratio is 36.90%.

Wall Street Analysts Forecast Growth

LMAT has been the subject of several recent research reports. Freedom Capital raised LeMaitre Vascular to a “hold” rating in a report on Tuesday, March 31st. Roth Mkm reissued a “buy” rating and set a $117.00 price objective (up from $108.00) on shares of LeMaitre Vascular in a report on Thursday, February 26th. Weiss Ratings raised LeMaitre Vascular from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, May 20th. Barrington Research reissued an “outperform” rating and set a $120.00 price objective on shares of LeMaitre Vascular in a report on Wednesday, June 3rd. Finally, Citizens Jmp boosted their price objective on LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a report on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $112.60.

Insider Activity

In other news, Director Bridget A. Ross sold 5,044 shares of the company’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $111.10, for a total value of $560,388.40. Following the completion of the sale, the director directly owned 3,942 shares of the company’s stock, valued at $437,956.20. This represents a 56.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO George W. Lemaitre sold 27,881 shares of the company’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $108.69, for a total value of $3,030,385.89. Following the completion of the sale, the chief executive officer directly owned 1,430,019 shares of the company’s stock, valued at approximately $155,428,765.11. This trade represents a 1.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 54,453 shares of company stock valued at $5,906,174 in the last ninety days. 7.40% of the stock is owned by insiders.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.